Articles from Mosaic Therapeutics

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth.

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Thomas Fuchs as CEO. Thomas will lead the Company to advance its pipeline of proprietary drug combination programmes into the clinic, and through a planned Series B financing round.

Mosaic Therapeutics, Ltd (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies for patients, today announces the in-licensing of two clinical-stage oncology programs from Astex Pharmaceuticals (‘Astex’), a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd. Mosaic has identified proprietary combinations incorporating the licensed products and their targets and this agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no, or limited, treatment options.

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company dedicated to resolving cancer’s complexity to power new treatments for patients, today announced the close of its $28 million series A funding round. The Company also announces the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital.